Paolo A. Ascierto, MD, National Tumor Institute, Milan, Italy, talks on current and future targeted therapies for melanoma. Targeted therapy is particularly important in the context of melanoma, with at least half of patients carrying a BRAF mutation. These patients are currently treated with a combination of BRAF and MEK inhibitors in both metastatic and adjuvant settings. In addition, the combination of vemurafenib/cobimetinib and atezolizumab was recently approved by the FDA, based on data from the IMspire150 trial (NCT02908672) showing a significant improvement in progression-free survival (PFS) for the vemurafenib/cobimetinib and atezolizumab arm. Further results from trials evaluating different combinations are awaited, as well as evaluating novel tyrosine kinase inhibitors (TKI). This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

свернуть